Acquista Criptovalute
Paga con
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Mercati
Trading
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Opzioni
Hot
Trade European-style Vanilla Options
Conto unificato
Massimizza l'efficienza del tuo capitale
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Guadagna
Lancia
CandyDrop
tag
Raccogli le caramelle per guadagnare airdrop
Launchpool
Staking rapido, guadagna potenziali nuovi token
HODLer Airdrop
Fai holding GT e ottieni enormi airdrop gratuitamente
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investimento
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
Altro
Promozioni
AI
Altro
TradFi
WCTC S8
Rewards
IOVA

Prezzo Iovance Biotherapeutics Inc

Closed
IOVA
$3,60
+$0,10(+2,85%)

*Data last updated: 2026-05-10 01:54 (UTC+8)

As of 2026-05-10 01:54, Iovance Biotherapeutics Inc (IOVA) is priced at $3,60, with a total market cap of $1,29B, a P/E ratio of -2,49, and a dividend yield of 0,00%. Today, the stock price fluctuated between $3,38 and $3,62. The current price is 6,50% above the day's low and 0,55% below the day's high, with a trading volume of 18,88M. Over the past 52 weeks, IOVA has traded between $3,13 to $4,21, and the current price is -14,48% away from the 52-week high.

IOVA Key Stats

Yesterday's Close$3,55
Market Cap$1,29B
Volume18,88M
P/E Ratio-2,49
Dividend Yield (TTM)0,00%
Diluted EPS (TTM)0,85
Net Income (FY)-$390,97M
Revenue (FY)$263,50M
Earnings Date2026-08-06
EPS Estimate0,14
Revenue Estimate$87,68M
Shares Outstanding364,58M
Beta (1Y)0.688

About IOVA

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
SectorHealthcare
IndustryBiotechnology
CEOFrederick G. Vogt
HeadquartersSan Carlos,CA,US
Official Websitehttps://www.iovance.com
Employees (FY)975,00
Average Revenue (1Y)$270,25K
Net Income per Employee-$401,00K

Iovance Biotherapeutics Inc (IOVA) FAQ

What's the stock price of Iovance Biotherapeutics Inc (IOVA) today?

x
Iovance Biotherapeutics Inc (IOVA) is currently trading at $3,60, with a 24h change of +2,85%. The 52-week trading range is $3,13–$4,21.

What are the 52-week high and low prices for Iovance Biotherapeutics Inc (IOVA)?

x

What is the price-to-earnings (P/E) ratio of Iovance Biotherapeutics Inc (IOVA)? What does it indicate?

x

What is the market cap of Iovance Biotherapeutics Inc (IOVA)?

x

What is the most recent quarterly earnings per share (EPS) for Iovance Biotherapeutics Inc (IOVA)?

x

Should you buy or sell Iovance Biotherapeutics Inc (IOVA) now?

x

What factors can affect the stock price of Iovance Biotherapeutics Inc (IOVA)?

x

How to buy Iovance Biotherapeutics Inc (IOVA) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

IOVA
CFD
Fai trading

Hot Posts su Iovance Biotherapeutics Inc (IOVA)

VitaliksTwin

VitaliksTwin

05-08 13:17
Just spotted something interesting in the biotech space that's worth digging into. There's this company Iovance Biotherapeutics (IOVA) that's been flying under most investors' radar, but their recent performance suggests they could be set for a parabolic move if their pipeline continues to deliver. So here's the setup: Two years ago they got approval for lifileucel, marketed as Amtagvi, a TIL-based cancer treatment for melanoma. TIL therapy is actually pretty clever - they harvest your own tumor-infiltrating lymphocytes, supercharge them in the lab, then put them back to fight your specific cancer. It's personalized medicine at work. What caught my attention is the real-world data. In actual clinical conditions, Amtagvi hit a 52% objective response rate after two or fewer prior treatment lines. That's notably higher than the 31% from the trial data that originally got it approved. When real-world results beat trial data like that, it usually signals doctors will start prescribing more aggressively. The revenue picture is starting to show momentum too - they posted 13% quarter-over-quarter revenue growth to $68 million. Still not profitable, which is typical for biotech at this stage, but the trajectory is there. They're also running multiple phase 2 studies with lifileucel across different cancer types and in combination with other treatments. That's the kind of pipeline activity that could unlock additional indications down the line. Here's why I think this could go parabolic: You can still grab shares under $3, and if even one or two of those pipeline candidates move forward successfully, the market will likely reprice this significantly. The company has proven the core technology works, revenue is starting to flow, and they've got multiple shots on goal with their trials. Obviously biotech is high-risk, high-reward territory. But when you find a company with an approved product generating real revenue, clinical data that's beating expectations, and a pipeline that could unlock major catalysts - that's the kind of risk-reward setup that could deliver outsized returns if things break right. Worth keeping on your watchlist at minimum.
0
0
0
0
fren_with_benefits

fren_with_benefits

04-30 16:00
Been looking at Iovance Biotherapeutics (IOVA) lately and there's actually something interesting happening here if you're willing to take on serious risk. Their main product Amtagvi just got FDA approval for melanoma early last year, and the commercial traction has been solid. FY2025 revenue hit $263.5 million, which is a 60.6% jump year-over-year. Not bad for a biotech company still in early commercialization phase. They're also pushing into Europe, UK, and Australia for melanoma, plus they got approval in Canada already. What caught my attention though is the expansion potential. They're testing Amtagvi across multiple cancer types and just got Fast Track Designation from the FDA for non-small cell lung cancer treatment. If they can capture even a decent slice of a massive market like NSCLC over the next decade through 2036, this stock could legitimately move. But here's the catch—and it's a big one. Amtagvi is basically a personalized cell therapy, which means it's complex as hell. They have to extract patient cells, manufacture the drug for each individual person, then administer it via IV after chemo. The whole process takes about 34 days and can only happen at specialized centers with trained staff. This isn't a simple pill you pop. The manufacturing costs and logistical complexity are brutal, which makes profitability a real question mark. Plus you've got all the usual biotech landmines: clinical setbacks, regulatory hurdles, execution risk. This is the kind of stock that either moons or tanks depending on how well they navigate the next few years. So yeah, if you're comfortable with high volatility and the real possibility of losing money, there's potential here. But this definitely isn't for risk-averse investors. Do your own research before touching this one.
0
0
0
0
ChainSauceMaster

ChainSauceMaster

04-30 15:48
Been looking at some biotech plays lately and there's one that's been catching my attention. Iovance Biotherapeutics—ticker IOVA—is a penny stock that could genuinely reshape a portfolio if things break right over the next decade. Here's the thing: their lead product Amtagvi just got approval for melanoma back in early 2024. It's basically a personalized cancer therapy manufactured from patients' own cells. Sounds wild, right? The commercial traction has actually been solid despite some stock price weakness. FY2025 revenue hit $263.5 million, up over 60% year-over-year. Most of that's coming from Amtagvi. They're not just sitting on melanoma either. Amtagvi is being studied across multiple cancer types. They got Fast Track Designation from the FDA for non-small cell lung cancer treatment, which basically means the development process gets accelerated. They're also pushing for approvals in the EU, UK, and Australia. If they can crack into a massive market like NSCLC, the upside could be substantial. But here's where it gets tricky. The manufacturing process is genuinely complex. You've got to extract patients' cells, manufacture the treatment individually for each person, then administer it via IV after chemotherapy. The whole process takes about 34 days. It can only be given at specialized centers with trained staff. That's expensive infrastructure, and it's going to weigh on profitability for a while. There are also the standard biotech risks—clinical setbacks could tank the stock, regulatory hurdles could delay approvals, execution could falter. This isn't a play for risk-averse investors. That said, if Iovance navigates all these obstacles and Amtagvi captures meaningful market share in cancer treatment, shares could absolutely skyrocket. The cancer therapy space is massive, and personalized treatments are getting serious attention. But you need to be comfortable with significant volatility and the real possibility this doesn't work out. Do your homework before touching penny stocks like this one.
0
0
0
0